- Home
- FORM vs MLYS Comparison
FORM vs MLYS Comparison
Compare FORM & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORM
- MLYS
- Stock Information
- Founded
- FORM 1993
- MLYS 2019
- Country
- FORM United States
- MLYS United States
- Employees
- FORM N/A
- MLYS N/A
- Industry
- FORM Semiconductors
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- FORM Technology
- MLYS Health Care
- Exchange
- FORM Nasdaq
- MLYS Nasdaq
- Market Cap
- FORM 2.7B
- MLYS 3.1B
- IPO Year
- FORM N/A
- MLYS 2023
- Fundamental
- Price
- FORM $39.69
- MLYS $38.06
- Analyst Decision
- FORM Buy
- MLYS Strong Buy
- Analyst Count
- FORM 8
- MLYS 6
- Target Price
- FORM $38.14
- MLYS $42.60
- AVG Volume (30 Days)
- FORM 942.8K
- MLYS 1.6M
- Earning Date
- FORM 10-29-2025
- MLYS 11-10-2025
- Dividend Yield
- FORM N/A
- MLYS N/A
- EPS Growth
- FORM N/A
- MLYS N/A
- EPS
- FORM 0.57
- MLYS N/A
- Revenue
- FORM $764,554,000.00
- MLYS N/A
- Revenue This Year
- FORM $2.58
- MLYS N/A
- Revenue Next Year
- FORM $7.33
- MLYS N/A
- P/E Ratio
- FORM $69.83
- MLYS N/A
- Revenue Growth
- FORM 8.30
- MLYS N/A
- 52 Week Low
- FORM $22.58
- MLYS $8.24
- 52 Week High
- FORM $50.79
- MLYS $41.09
- Technical
- Relative Strength Index (RSI)
- FORM 74.52
- MLYS 62.11
- Support Level
- FORM $34.80
- MLYS $37.32
- Resistance Level
- FORM $40.86
- MLYS $40.51
- Average True Range (ATR)
- FORM 1.51
- MLYS 2.09
- MACD
- FORM 0.50
- MLYS -0.77
- Stochastic Oscillator
- FORM 88.07
- MLYS 43.86
About FORM FormFactor Inc. FormFactor Inc.
FormFactor Inc is a provider of electrical and optical test and measurement technologies along the full semiconductor product lifecycle - from characterization, modeling, reliability, and design de-bug, to qualification and production test.. The company operates in two reportable segments namely Probe Cards Segment and the Systems Segment. Sales of probe cards and analytical probes are included in the Probe Cards Segment, while sales of probe stations and thermal sub-systems are included in the Systems Segment. Probe cards generate the maximum revenue from its operations. It offers multiple product lines which include analytical probes, probe stations, thermal sub-systems, and related services.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.